Baxter Seeks OK to Sell New Hemophilia Drug

December 4, 2014

Baxter International submitted an application to the Food and Drug Administration for the approval of a key hemophilia drug. The drug, BAX 855, is an extended-release version of its flagship hemophilia drug Advate, which is sold in dozens of countries. The treatment is seen as a key part of the company’s drug pipeline and its […]

Sign up for E-mails, Dateline Magazine, and other ways to stay connected.